OMKAR PHARMACHEM | CIPLA | OMKAR PHARMACHEM/ CIPLA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 116.1 | 32.8 | 353.9% | View Chart |
P/BV | x | 2.5 | 4.0 | 61.5% | View Chart |
Dividend Yield | % | 0.0 | 0.5 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
OMKAR PHARMACHEM Mar-21 |
CIPLA Mar-22 |
OMKAR PHARMACHEM/ CIPLA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 21 | 1,083 | 1.9% | |
Low | Rs | 16 | 806 | 2.0% | |
Sales per share (Unadj.) | Rs | 0.3 | 269.7 | 0.1% | |
Earnings per share (Unadj.) | Rs | 0.2 | 31.7 | 0.7% | |
Cash flow per share (Unadj.) | Rs | 0.2 | 44.8 | 0.5% | |
Dividends per share (Unadj.) | Rs | 0 | 5.00 | 0.0% | |
Avg Dividend yield | % | 0 | 0.5 | 0.0% | |
Book value per share (Unadj.) | Rs | 8.6 | 257.8 | 3.3% | |
Shares outstanding (eoy) | m | 10.08 | 806.81 | 1.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 68.4 | 3.5 | 1,951.8% | |
Avg P/E ratio | x | 83.3 | 29.8 | 279.8% | |
P/CF ratio (eoy) | x | 82.9 | 21.1 | 393.0% | |
Price / Book Value ratio | x | 2.1 | 3.7 | 58.1% | |
Dividend payout | % | 0 | 15.8 | 0.0% | |
Avg Mkt Cap | Rs m | 185 | 762,177 | 0.0% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 1 | 35,299 | 0.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 3 | 217,633 | 0.0% | |
Other income | Rs m | 0 | 3,217 | 0.0% | |
Total revenues | Rs m | 3 | 220,851 | 0.0% | |
Gross profit | Rs m | 0 | 43,298 | 0.0% | |
Depreciation | Rs m | 0 | 10,520 | 0.0% | |
Interest | Rs m | 1 | 1,064 | 0.1% | |
Profit before tax | Rs m | 0 | 34,933 | -0.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -3 | 9,338 | -0.0% | |
Profit after tax | Rs m | 2 | 25,595 | 0.0% | |
Gross profit margin | % | 8.1 | 19.9 | 40.6% | |
Effective tax rate | % | 714.7 | 26.7 | 2,673.7% | |
Net profit margin | % | 82.0 | 11.8 | 697.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1 | 147,108 | 0.0% | |
Current liabilities | Rs m | 10 | 49,129 | 0.0% | |
Net working cap to sales | % | -332.1 | 45.0 | -737.7% | |
Current ratio | x | 0.1 | 3.0 | 2.4% | |
Inventory Days | Days | 12,572 | 63 | 19,998.9% | |
Debtors Days | Days | 365 | 6 | 6,355.3% | |
Net fixed assets | Rs m | 93 | 119,415 | 0.1% | |
Share capital | Rs m | 101 | 1,614 | 6.2% | |
"Free" reserves | Rs m | -14 | 206,364 | -0.0% | |
Net worth | Rs m | 87 | 207,977 | 0.0% | |
Long term debt | Rs m | 0 | 4,162 | 0.0% | |
Total assets | Rs m | 94 | 266,523 | 0.0% | |
Interest coverage | x | 0.4 | 33.8 | 1.1% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0 | 0.8 | 3.5% | |
Return on assets | % | 3.0 | 10.0 | 29.7% | |
Return on equity | % | 2.6 | 12.3 | 20.8% | |
Return on capital | % | 0.2 | 17.0 | 1.4% | |
Exports to sales | % | 0 | 26.2 | 0.0% | |
Imports to sales | % | 0 | 8.2 | 0.0% | |
Exports (fob) | Rs m | NA | 57,094 | 0.0% | |
Imports (cif) | Rs m | NA | 17,803 | 0.0% | |
Fx inflow | Rs m | 0 | 60,180 | 0.0% | |
Fx outflow | Rs m | 0 | 17,803 | 0.0% | |
Net fx | Rs m | 0 | 42,376 | 0.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | 33,259 | 0.0% | |
From Investments | Rs m | NA | -18,719 | 0.0% | |
From Financial Activity | Rs m | NA | -15,998 | 0.0% | |
Net Cashflow | Rs m | 0 | -1,323 | -0.0% |
Indian Promoters | % | 0.0 | 13.5 | 0.2% | |
Foreign collaborators | % | 0.0 | 20.1 | - | |
Indian inst/Mut Fund | % | 0.0 | 49.0 | - | |
FIIs | % | 0.0 | 27.6 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 100.0 | 66.4 | 150.6% | |
Shareholders | 3,561 | 418,910 | 0.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare OMKAR PHARMACHEM With: SUN PHARMA DR. REDDYS LAB LUPIN AUROBINDO PHARMA ZYDUS LIFESCIENCES
Indian share markets rose today tracking the rally in US stocks after softer-than-expected US inflation data stoked speculation the Federal Reserve could pivot to a shallower pace of interest-rate hikes.